Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
February 26, 2020 4:05 PM ESTROCKVILLE, Md., Feb. 26, 2020 /PRNewswire/ --
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery approaches Additional interim data from RGX-121 Phase I/II trial for MPS II expected in 2020 Plans to expand rare disease pipeline into neuromuscular disorders in 2H 2020 $400 million in cash, cash equivalents and marketable securities as of December 31, 2019 Conference call Wednesday, February 26th at... More